Aromasin
Aromasin is exemestane, a drug that reduces estrogen production. The reference information distinguishes community starting amounts, studied doses and its medical label.
Technical catalog description
Exemestane is a steroidal AI that permanently binds to and destroys the aromatase enzyme. Unlike reversible [AIs] like Anastrozole, exemestane’s effects persist even after discontinuation until new aromatase enzymes are produced.
This ‘suicidal’ mechanism makes exemestane particularly effective for estrogen control, but also makes it easier to crash estrogen levels if overdosed. Many users prefer exemestane because it has less negative impact on lipids compared to other [AIs] and may have mild androgenic effects.
Read next
Mechanism details
Exemestane lowers estrogen production by inactivating aromatase, the enzyme that converts androgens into estrogens. It is sold as Aromasin for specific breast-cancer indications. Its irreversible action means that the drug leaving the bloodstream does not immediately restore the enzyme’s activity. The male pharmacokinetic study describes this mechanism.
Low-estrogen symptoms, fatigue, and overcorrection that lasts beyond one dose
GI upset or joint dryness in some users
estradiol
lipid panel
Already-low estradiol or joint and mood symptoms from low estrogen
Aggressive dosing as a just-in-case add-on
Community use context
Steroid users discuss exemestane for estrogen management. An amount reported in a community guide describes that guide’s starting point. It does not establish that someone needs an aromatase inhibitor or that the same amount fits TRT, a different steroid exposure, or a different person.
Source conflicts
The Estrogen Handbook and the dedicated Aromasin profile give different starting frequencies. The dedicated profile also later describes daily administration, contradicting its own once-or-twice-weekly starting statement. These statements are retained separately below.
Both pages cite the same small, short-term male study for pharmacology. Two wiki pages repeating that citation are not two independent studies. The study tested daily oral treatment in healthy young subjects, not the wiki’s starting regimen during steroid use.
Risks and monitoring
The community handbook describes individual variation and the need for bloodwork. The Aromasin label includes bone-density loss and other warnings in its treated population. Community popularity does not establish safety, and a reported starting amount is not a safety threshold.
Source reference information
Context-dependent starting reference · cadence conflict. The community pages disagree on frequency and individual response matters. Neither oncology labeling nor a short male study resolves this PED starting regimen. References remain separate from quantities entered in a plan.
Starting: 12.5 mg/administration. Every 3 days OR every 3.5 days. Handbook starting reference in its 500–600 mg testosterone example; the testosterone time basis is not stated in that sentence. Population: Steroid users discussed by the wiki. Route: oral; formulation: unspecified in this claim. Dosing is user-dependent; the source calls for bloodwork and says frequency varies. The surrounding text describes oral exemestane, but no product, tablet strength or split-tablet accuracy is specified. The cited small male study did not test this starting reference. Source conflict: profile_start, profile_daily. Source: r/steroids: The Estrogen Handbook.
Starting: 12.5 mg/administration. Once OR twice per week. Dedicated profile starting reference, individualized to response. Population: Strength athletes/bodybuilders discussed by the profile. Route: oral; formulation: unspecified in this claim. Frequency differs from the Handbook. This page also later describes daily administration; no internally consistent universal schedule. Source conflict: handbook_start, profile_daily. Source: r/steroids: Aromasin.
Cadence only: Cadence-only statement. Roughly once every 24 hours. Separate daily-cadence assertion later in Use/Dosing; not attached to the 12.5 mg starting amount. Population: Users discussed by the profile. Route: oral; formulation: unspecified in this claim. Contradicts the once/twice-weekly start in the same section. No quantity is assigned to this cadence-only claim. Source conflict: handbook_start, profile_start. Source: r/steroids: Aromasin.
Studied: 25 mg/day total. Daily. Short crossover study of estrogen suppression and pharmacokinetics. Population: 12 healthy eugonadal subjects aged 14–26. Route: oral; formulation: Exemestane used in the study; exact presentation not described in abstract. Source duration: 10 days per treatment period; 14-day washout. Small, short-term study; not PED-cycle or TRT dosing validation. Long-term efficacy and safety require further study. Source: Mauras et al., exemestane in young males.
Studied: 50 mg/day total. Daily. Second studied dose in the same experiment, not independent corroboration. Population: Same 12 subjects in the crossover study. Route: oral; formulation: Study presentation unspecified in abstract. Source duration: 10 days per treatment period. Same study and limitations as the 25 mg arm; not a community starting regimen. Source: Mauras et al., exemestane in young males.
Label regimen: 25 mg/day total. Once daily after a meal. Aromasin oncology label reference. Population: Postmenopausal women with labeled early or advanced breast-cancer indications. Route: oral; formulation: Aromasin 25 mg tablet. Different population and indication from PED or TRT use. Label includes reductions in bone mineral density and other warnings; dose is not a safety threshold. Source: Aromasin prescribing information.